Avalo Therapeutics, Inc. (AVTX) Form 424B3 — Jul 28, 2026
Avalo Therapeutics filed a prospectus supplement covering the resale of up to 128,189 shares of common stock by certain selling stockholders. These shares were issued to former stockholders of AlmataBio, Inc. in connection with the Milestone Buyout Amendment Agreement dated April 26, 2026. The company stated that it will not receive any proceeds from the sale of these shares.
Key figures
- Offering Price
- 19.5
- Shares Offered
- 128189
- Shares Outstanding
- 52902989
- Par Value
- 0.001
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.